Skip to Content

United Therapeutics Corp UTHR Stock Quote

| Rating as of


Last close prices updated as of Feb 03, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 259.48
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Mid Blend
  • Day Range 252.30  –  262.77
  • Year Range 158.38  –  283.09
  • Market Cap 11.5219 Bil
  • Volume / Avg 500,781.0 /  369,559.0
  • Price / Sales 6.71
  • Price / Book 2.59
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis UTHR

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


United Therapeutics Continues to Face Generic Competition Amid Approval of Tyvaso DPI; FVE $213

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

United Therapeutics specializes in therapies for pulmonary arterial hypertension, or high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the molecule, treprostinil. Its marketed PAH portfolio includes Remodulin (subcutaneous or intravenous administration), Tyvaso (inhaled), Orenitram (oral), and Adcirca (oral). The company also sells Unituxin for high-risk neuroblastoma, but we do not consider oncology to be United Therapeutics' core competency. The company has long been a leader in the prostacyclin market for PAH, but we expect its competitive position will be challenged by generic entry as well as Johnson & Johnson's Uptravi, which J&J gained through its acquisition of Actelion in 2017. Uptravi (oral selexipag) has quickly gained share, propelled by strong clinical data, and we expect it will remain a key competitor against United's products, particularly pipeline candidate ralinepag.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics UTHR

Company Profile UTHR

Business Description

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

1040 Spring Street
Silver Spring, MD, 20910
Industry Biotechnology
Employees 965

Related Articles UTHR

FAQs for United Therapeutics Corp Stock

No. UTHR does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

UTHR’s market cap is 11.52 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

UTHR’s stock style is Mid Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

UTHR’s price/sales is 6.71.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

UTHR’s price/forward earnings is 13.46.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

UTHR’s price/book is 2.59.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See UTHR’s valuation ratios compared to the Market Index.

UTHR’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare UTHR’s historical performance against its industry peers and the overall market.